Aug 10, 2022 12:44 PM IST

Pfizer MD Sridhar resigns

Sridhar has expressed his intention to take early retirement and has tendered his resignation, the company said in a regulatory filing.

Hold Pfizer; target of Rs 4480: ICICI Direct

ICICI Direct recommended hold rating on Pfizer with a target price of Rs 4480 in its research report dated August 06, 2022.

Pfizer Standalone June 2022 Net Sales at Rs 592.90 crore, down 20.86% Y-o-Y

COVID-19 | All you need to know about Paxlovid, the Pfizer drug prescribed to US President Joe Biden

US President Joe Biden tested positive for COVID-19 on July 21. He is experiencing mild symptoms and will continue working, the White House said.

Pfizer India, Max Hospitals join hands to promote research on drug efficacy

The research will focus on prevention, treatment and management of diseases that are of public health priority in India such as cancer and cardiovascular diseases

U.S. FDA advisers back COVID vaccines for children as young as 6 months

On Wednesday, a panel of FDA advisers unanimously recommended that the agency approve COVID-19 vaccinations from Moderna Inc and Pfizer Inc/BioNTech SE for millions of youngsters in the United States.

Pfizer to exit GSK's consumer health arm after spin-off

Pfizer previously signalled it would seek to sell its shareholding in Haleon, the world's largest consumer health business and home to Sensodyne toothpaste and Advil painkillers.

Pfizer to offer low-cost medicines, vaccines to world's poorest countries

US pharmaceutical giant Pfizer on Wednesday said it would sell its patented drugs at a not-for-profit basis to the world's poorest countries, as part of a new initiative announced at the World Economic Forum in Davos.

Buy Pfizer; target of Rs 4810: ICICI Direct

ICICI Direct recommended hold rating on Pfizer with a target price of Rs 4810 in its research report dated May 23, 2022.

Pfizer/BioNTech say 3 COVID shots elicit good response in children under 5

Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.

Pfizer/BioNTech say 3 COVID shots generate good response in under-5s

The companies said the vaccine was safe and well-tolerated by the children, and they plan to soon ask global regulators to authorize the shot for the age group, children for whom no vaccine is currently approved in most of the world.

Pfizer Standalone March 2022 Net Sales at Rs 549.66 crore, up 2.79% Y-o-Y

US CDC urges Pfizer booster for children ages 5 to 11

Pfizer and its partner BioNTech currently make the only COVID-19 vaccine available for children of any age in the U.S. Those ages 5 to 11 receive a dose that’s one-third the amount given to everyone 12 and older.

US FDA authorizes Pfizer's COVID booster shot for young children

The authorization makes everyone in the United States aged five and above eligible for booster doses of the vaccine.

Fourth COVID-19 vaccine dose provides strong immunity boost: UK study

The findings, published in The Lancet Infectious Disease journal, show that fourth dose mRNA booster vaccines for COVID-19 are well-tolerated in people who received Pfizer as a third dose.

Cash-rich Pfizer to pay $11.6 billion for Biohaven in biggest deal since 2016

The deal, announced on Tuesday, will give Pfizer access to Biohaven's approved rimegepant, a potential blockbuster that belong to a class of migraine treatments known as calcitonin gene-related peptide (CGRP) inhibitors.

Pfizer opens $20-million global drug development centre at IIT-Madras

The centre, the first in Asia, will be a part of a network of 12 such facilities to be set up worldwide

Pfizer sets up Asia's first global drug development centre in Chennai

The centre, which employs 250 scientists and technicians, would develop innovative formulations, small molecules and active pharmaceutical ingredients (APIs).

Pfizer Q1 revenues jump 77% to $25.7 billion on COVID-19 vaccine

The major American drugmaker reported revenues of $25.7 billion for the first quarter, up 77 percent from the year-ago period, with the COVID vaccine taking in $13.2 billion.

No end in sight for India’s wait for Paxlovid, the most promising COVID-19 drug yet, despite surging cases

Late-stage clinical trials showed Paxlovid cut hospitalisation and death risks in mild to moderately high-risk COVID-19 patients by up to 88 percent and new evidence is emerging that it is also dramatically effective in treating long COVID symptoms

Google's Sundar Pichai to co-chair council to help Ukranian, Afghan refugees settle in US

Other CEOs involved with the initiative include Apple's Tim Cook, Adobe's Shantanu Narayen, Bank of America's Brian Moynihan, Microsoft's Brad Smith and Pfizer's Albert Bourla.

Pfizer offers voluntary retirement scheme for field staff

Over the past few years, the company has been on a journey to reshape itself into a more growth-oriented and innovative biopharma company, Pfizer said in a regulatory filing.

Second booster shields elderly from COVID but protection wanes quickly: Study

Protection against severe illness did not wane during the six weeks after the dose but more follow-up study was needed to evaluate its longer-term protection, the researchers said.

Pfizer vaccine less effective against COVID-19 in kids aged 5-11: Study

Researchers from the New York State Department of Health and the University at Albany School of Public Health, US, estimated the effectiveness of Pfizer vaccine against COVID cases and hospitalisations.

South Korea approves Pfizer's COVID vaccine for ages 5-11

The Korea Disease Control and Prevention Agency reported a record 171,452 new virus cases on Wednesday, nearly a 40-fold increase from levels in mid-January when omicron first emerged as the country’s dominant strain.